

# WOAH Reference Laboratory Reports Activities 2023

## Activities in 2023

This report has been submitted : 12 juin 2024 05:26

### Laboratory Information

<b>Name of disease (or topic) for which you are a designated WOA Reference Laboratory:</b>	Infectious bursal disease (Gumboro disease)
<b>Address of laboratory:</b>	Division of Avian Immunosuppressive Disease Harbin Veterinary Research Institute (HVRI) Chinese Academy of Agricultural Sciences (CAAS) 678 Haping Road Xiangfang District Harbin 150069 CHINA (PEOPLES REP. OF)
<b>Tel.:</b>	+8618945083045
<b>E-mail address:</b>	gaoyulong@caas.cn
<b>Website:</b>	
<b>Name (including Title) of Head of Laboratory (Responsible Official):</b>	Dr. Zhigao Bu, the director of HVRI, CAAS
<b>Name (including Title and Position) of WOA Reference Expert:</b>	Dr. Yulong Gao
<b>Which of the following defines your laboratory? Check all that apply:</b>	Governmental Research agency Academic institution

### TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.?

(Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOA Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
ELISA Ab detection		432	0
Direct diagnostic tests			
virus isolation		2	0
Virus titration in chicken embryo		4	0
virus isolation or titration in cells		4	0
indirect immunofluorescence assay (IFA) in cells		40	0
Preparation of virus stocks from infected bursa		4	0
Virus gene sequencing of VP2 or VP1		92	0
Complete virus genome sequencing		2	0

### TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?

No

3. Did your laboratory supply standard reference reagents (nonWOA-approved) and/or other diagnostic reagents to WOA Members?

No

4. Did your laboratory produce vaccines?

Not applicable

5. Did your laboratory supply vaccines to WOAHP Members?

Not applicable

**TOR3: NEW PROCEDURES**

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOAHP Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

Yes

NAME OF THE NEW VACCINE DEVELOPED	DESCRIPTION AND REFERENCES (PUBLICATION, WEBSITE, ETC.)
The IBD live vaccine	It is currently under review by the Ministry of Agriculture and Rural Affairs of China
The recombinant MDV vaccine expressing IBDV VP2	It is currently under review by the Ministry of Agriculture and Rural Affairs of China
The subunit vaccine against IBDV	The laboratory evaluation has been completed

9. Did your laboratory validate vaccines according to WOAHP Standards for the designated pathogen or disease?

No

**TOR4: DIAGNOSTIC TESTING FACILITIES**

10. Did your laboratory carry out diagnostic testing for other WOAHP Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAHP Member?

Yes

NAME OF THE WOAHP MEMBER COUNTRY RECEIVING A TECHNICAL CONSULTANCY	PURPOSE	HOW THE ADVICE WAS PROVIDED
POLAND	Review grant proposal for the National Science Center, Poland	Online review system (February 4, 2023)
FRANCE	Reference Laboratory Questionnaire	Online Survey questionnaire (June 26, 2023)
UNITED KINGDOM	WOAHP Lab Twinning Participation Survey	Online Survey questionnaire (July 11, 2023)

**TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES**

12. Did your laboratory participate in international scientific studies in collaboration with WOAHP Members other than the own?

No

13. In exercising your activities, have you identified any regulatory research needs\* relevant for WOAHP?

No

**TOR6: EPIZOOLOGICAL DATA**

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

Relevant information was collected from the publication.

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

Disseminate the epidemiological data through the published paper and the academic report.

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

3

- [1] Jiang N, Wang GD, Zhang WY, Wang YL, Niu XX, Huang MM, Gao L, Li K, Cui HY, Liu CJ, Zhang YP, Bao KY, Wang SY, Chen YT, Wang XM, Gao YL, Qi XL. A single mutation of VP2 is responsible for the lethality and antigenicity differences between novel variant and very virulent IBDV strains. *Transboundary and Emerging Diseases*, 2023, 6684304.
- [2] Mi JL, He TN, Hu XY, Wang Z, Wang T, Qi X, Li K, Gao L, Liu C, Zhang Y, Wang S, Qiu Y, Liu Z, Song J, Wang X, Gao YL, Cui HY. *Enterococcus faecium* C171: Modulating the Immune Response to Acute Lethal Viral Challenge. *Int J Antimicrob Agents*. 2023, 62(5):106969.
- [3] Li KL, Niu XX, Jiang N, Zhang W, Wang G, Li K, Huang M, Gao YL, Qi XL, Wang XM. Comparative Pathogenicity of Three Strains of Infectious Bursal Disease Virus Closely Related to Poultry Industry. *Viruses*. 2023, 15(6):1257.
- [4] Qi XL, Wang XM, Gao YL. The Epidemic Situation and New Epidemic of Infectious Bursal Disease in China. *Poultry farming and prevention and control of poultry diseases (in Chinese)*. 2023, 8: 23-28.
- [5] Li XH, Yang FC, Liu R, Gao L, Cui HY, Zhang YP, Liu CJ, Qi XL, Wang XM, Gao YL, Li K. Construction and biological characteristics analysis of a recombinant turkey herpesvirus expressing the VP2 gene of infectious bursal disease virus in chickens. *Journal of Animal Husbandry and Veterinary Medicine (in Chinese)*. 2023, 54(2): 656-662.

b) International conferences:

1

- [1] The XXII World Veterinary Poultry Association Congress. Oral presentation, the sudden epidemic, immune escape, vaccine development of novel variant infectious bursal disease virus (nVarIBDV). Verona, Italy, September 4-8, 2023.
- [2] The XXII World Veterinary Poultry Association Congress. Oral presentation, Molecular Mechanism of Host factor OASL regulating the replication of infectious Bursal disease virus. Verona, Italy, September 4-8, 2023.
- [3] The 12th Asia Pacific Poultry Conference. Oral presentation, Genetic variation and new epidemic characteristics of infectious bursal disease. Nanjing, China, October 31-December 3, 2023.

c) National conferences:

1

- [1] The 15th National Immunology Academic Conference. Oral presentation, The molecular mechanism of host factor OASL regulating the replication of infectious bursal disease virus. Suzhou, China, November 5, 2023.

d) Other (Provide website address or link to appropriate information):

0

## TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAHP Members?

No

## TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO/IEC 17025:2017	CNAS certificate	CNAS Certificate.pdf

19. Is your quality management system accredited?

Yes

	Accreditation body
--	--------------------

Test for which your laboratory is accredited	
Isolation and Identification of Infectious Bursal Disease Virus	CNAS
RT-PCR Assay for Detecting Infectious Bursal Disease Virus	CNAS
ELISA for Antibody Detection of Infectious Bursal Disease Virus	CNAS

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

China's Regulation on Biosafety Management of Pathogenic Microbiology Laboratory

### **TOR9: SCIENTIFIC MEETINGS**

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAHP?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAHP?

No

### **TOR10: NETWORK WITH WOAHP REFERENCE LABORATORIES**

23. Did your laboratory exchange information with other WOAHP Reference Laboratories designated for the same pathogen or disease?

Yes

24. Do you network (collaborate or share information) with other WOAHP Reference Laboratories designated for the same pathogen?

No

25. Did you organise or participate in inter-laboratory proficiency tests with WOAHP Reference Laboratories designated for the same pathogen?

No

26. Did your laboratory collaborate with other WOAHP Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

### **TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING**

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAHP Reference Laboratories for the same pathogen?

No

### **TOR12: EXPERT CONSULTANTS**

28. Did your laboratory place expert consultants at the disposal of WOAHP?

No

29. Additional comments regarding your report:

No